<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">farmaec</journal-id><journal-title-group><journal-title xml:lang="en">FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology</journal-title><trans-title-group xml:lang="ru"><trans-title>ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2070-4909</issn><issn pub-type="epub">2070-4933</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2070-4909.2017.10.2.041-043</article-id><article-id custom-type="elpub" pub-id-type="custom">farmaec-190</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group></article-categories><title-group><article-title>COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS</article-title><trans-title-group xml:lang="ru"><trans-title>Фармакоэкономический анализ стоимости антиретровирусных препаратов, применяемых в терапии ВИЧ-инфицированных пациентов</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кубаева</surname><given-names>М. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Kubaeva</surname><given-names>M. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры общей и клинической фармакологии, аспирант,</p><p>ул. Миклухо-Маклая, 10/3, Москва, 117198</p></bio><bio xml:lang="en"><p>Assistant of the Department of General and Clinical Pharmacology, post-graduate student,</p><p>ul. Miklukho-Maklaya, 10/3, Moscow, 117198</p></bio><email xlink:type="simple">kubaevamariyam@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гущина</surname><given-names>Ю. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Guchshina</surname><given-names>Y. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.фарм.н., доцент кафедры общей и клинической фармакологии,</p><p>ул. Миклухо-Маклая, 10/3, Москва, 117198</p></bio><bio xml:lang="en"><p>PhD, Associate Professor of the Department of General and Clinical Pharmacology,</p><p>ul. Miklukho-Maklaya, 10/3, Moscow, 117198</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГАОУ ВО «Российский университет дружбы народов»<country>Россия</country></aff><aff xml:lang="en">Peoples’ Friendship University of Russia<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>23</day><month>08</month><year>2017</year></pub-date><volume>10</volume><issue>2</issue><fpage>41</fpage><lpage>43</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kubaeva M.B., Guchshina Y.S., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Кубаева М.Б., Гущина Ю.Ш.</copyright-holder><copyright-holder xml:lang="en">Kubaeva M.B., Guchshina Y.S.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacoeconomics.ru/jour/article/view/190">https://www.pharmacoeconomics.ru/jour/article/view/190</self-uri><abstract><p>The aim of our study was to conduct a pharmacoeconomic and cost analysis of the therapeutic use of anti-HIV drugs.</p><sec><title>Material and methods</title><p>Material and methods. The study was based on the documented medical histories of HIV-infected patients; it also incorporated the data from the state-sponsored auctions and contracts for drug purchase, as well as the information from the website poisklekarstv.ru with recommendations for Moscow pharmacies. Both statistical and analytical approaches were used.</p></sec><sec><title>Results</title><p>Results. We found that all drugs needed for the treatment of patients with HIV infection are available in Russia. These drugs appear in the updated list of the treatment standards approved for domestic use in Russia.</p></sec><sec><title>Conclusion</title><p>Conclusion. The difference between the government-sponsored prices and the retail prices of these medications has an impact on the costs of ant-HIV therapy.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Цель исследования – проведение фармакоэкономического анализа стоимости антиретровирусных препаратов, применяемых в терапии ВИЧ-инфицированных пациентов.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Основным объектом исследования были приняты документированные истории болезни ВИЧ-инфицированных пациентов, данные государственных аукционов и контрактов на закупку лекарственных средств (ЛС), а также данные с сайта poisklekarstv.ru для аптек и аптечных сетей г. Москвы. Использованы статистический и аналитический методы анализа.</p></sec><sec><title>Результаты</title><p>Результаты. Согласно результатам проведенного анализа было установлено, что на данный момент в России имеются все препараты, необходимые для лечения пациентов с ВИЧ-инфекцией, входящие в современный перечень стандартов лечения согласно отечественным рекомендациям, а также установлена разница в стоимости антиретровирусных препаратов по розничной цене и цене государственного финансирования.</p></sec><sec><title>Заключение</title><p>Заключение. Разница в стоимости антиретровирусных препаратов по цене государственного финансирования и по розничной цене оказывает влияние на затраты при терапии ВИЧ-инфицированных пациентов. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>Фармакоэкономический анализ</kwd><kwd>ВИЧ</kwd><kwd>антиретровирусная терапия</kwd><kwd>стоимость</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Pharmacoeconomic analysis</kwd><kwd>HIV</kwd><kwd>antiretroviral therapy</kwd><kwd>costs</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Покровский В. В. ВИЧ-инфекция и СПИД: клинические рекомендации. Федеральный научно-методический центр по профилактике и борьбе со СПИДом. М. 2010; 187 с.</mixed-citation><mixed-citation xml:lang="en">Pokrovsky V. V. HIV infection and AIDS: clinical recommendations / Federal Scientific and Methodological Center for AIDS Prevention and Control; Ch. Ed. V. V. Pokrovsky [VICh-infektsiya i SPID: klinicheskie rekomendatsii. Federal’nyi nauchno-metodicheskii tsentr po profilaktike i bor’be so SPIDom (in Russian)]. Moscow. 2010; 187 p.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">De Cock K. M., Ekpini E., Gnaore E., Kadio A., Gayle H. D. The public health implications of AIDS research in Africa. JAMA. 1994; 272 (6): 481-486.</mixed-citation><mixed-citation xml:lang="en">De Cock K. M., Ekpini E., Gnaore E., Kadio A., Gayle H. D. The public health implications of AIDS research in Africa. JAMA. 1994; 272 (6): 481-486.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dixon S., McDonald S., Roberts J. The impact of HIV and AIDS on Africa’s economic development. BMJ. 2002; 324 (7331): 232-234.</mixed-citation><mixed-citation xml:lang="en">Dixon S., McDonald S., Roberts J. The impact of HIV and AIDS on Africa’s economic development. BMJ. 2002; 324 (7331): 232-234.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rosen S., Vincent J. R., MacLeod W., Fox M., Thea D. M., Simon J. L. The cost of HIV/AIDS to businesses in southern Africa. AIDS. 2004; 18 (2): 317-324.</mixed-citation><mixed-citation xml:lang="en">Rosen S., Vincent J. R., MacLeod W., Fox M., Thea D. M., Simon J. L. The cost of HIV/AIDS to businesses in southern Africa. AIDS. 2004; 18 (2): 317-324.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Umenai T., Narula M., Onuki D., Yamamoto T., Igari T. International HIV and AIDS prevention: Japan/United States collaboration. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 14 (2): 58-67.</mixed-citation><mixed-citation xml:lang="en">Umenai T., Narula M., Onuki D., Yamamoto T., Igari T. International HIV and AIDS prevention: Japan / United States collaboration. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 14 (Suppl 2): 58-67.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hecht R., Alban A., Taylor K., Post S., Andersen N. B., Schwarz R. Putting it together: AIDS and the millennium development goals. PLoS Med. 2006; 3 (11): e455.</mixed-citation><mixed-citation xml:lang="en">Hecht R., Alban A., Taylor K., Post S., Andersen N. B., Schwarz R. Putting it together: AIDS and the millennium development goals. PLoS Med. 2006; 3 (11): e455.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pavlos R., Phillips E. J. Individualization of antiretroviral therapy. Pharmgenomics Pers Med. 2012; 5: 1-17.</mixed-citation><mixed-citation xml:lang="en">Pavlos R., Phillips E. J. Individualization of antiretroviral therapy. Pharmgenomics Pers Med. 2012; 5: 1-17.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Покровский В. В. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекции. Эпидемиология и инфекционные болезни. Актуальные вопросы. 2012; 6: прил.</mixed-citation><mixed-citation xml:lang="en">Pokrovsky V. V. Protocols of dispensary observation and treatment of HIV-infected patients. Epidemiology and infectious diseases. Current issues. 2012; 6, app.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Рекомендации по клиническому ведению и лечению ВИЧ-инфицированных взрослых в Европе. Редакция от ноября 2009 г. Париж: Европейское клиническое общество по СПИД. 2012.</mixed-citation><mixed-citation xml:lang="en">Recommendations for the clinical management and treatment of HIV-infected adults in Europe, edition of November 2009. Paris: European Clinical Society for AIDS, 2012.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
